Trial Profile
Final results of a phase II study evaluating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NorBreast-228
- 21 Jan 2016 New trial record